CEFIXIME 200MG OFLOXACIN 200MG TABLETS

Envision designing an potent combination tablet consisting of two active pharmaceutical ingredients at 200MG each - a combination of skill, precision, and perfection. How do you design a dual-active tablet that preserves consistency of raw materials, uniformity of blends, and stability of finished product? This potent tablet makes an ideal new addition to your solid oral solid PCD Pharma Franchise range for commercial companies.

Here, the two active ingredients in the formulation are Cefixime and Ofloxacin, both being provided at a dosage of 200MG. The key issue is getting the precise amount of each ingredient dispensed with materials mixed evenly, throughout the batch. Certain excipients are key, as they improve powder flow, binding properties, lubrication, compression, disintegration, and overall structure of the finished product.

Dual-Active Powder Characterization and Blending

Cefixime and Ofloxacin have very different physical attributes – particle size, bulk density, flowability, moisture values, and compressibility - the considerations that are of concern as the company develops the formulation. What are the implications for blending and compression? Rough materials may be size-reduced before blending, and the manufacture may involve dry granulation or direct compression.

The challenge is to produce a homogenous distribution of all the active ingredients throughout the full excipient bed. Premixing can offset between-ingredient concentration variance or segregation. When active ingredients are present at the same strengths, concentration control within the final blend becomes a priority. Controlled time of mixing and mixing energy levels can achieve this.

Assays:Taking samples from different parts of the mix and performing assays verifies uniformity before compression. It is as important to control the moisture content as this is affected by environmental moisture and this also affects the flow and compression of the powders. Correct storage and manufacturing conditions can ensure reproducible processing.

Compression and Tablet Manufacturing Parameters

At this stage, the blend is compression molded into tablets with the use of appropriate tooling once the quality criteria are met. Compression force, tablet weight, thickness and hardness, rate of the press, and number of tablets per minute are all adjusted to the formulation and machine.

The compression process should generate a tablet with mechanical strength combined with adequate disintegration and dissolution properties. Optimization of the compression force should be obtained instead of maximization. Inprocess controls such as average tablet weight, variation of weights, thickness, hardness, friability, visual appearance are checked to ensure physical quality of the batch.

If a film coating forms part of the composition: The design focus is the physical parameters of the tablet core: spray rate, weight gain, drying conditions, adhesion, and surface uniformity. The coating system must be compatible with the active and excipient matrix, with uniform tablet dimensions minimizing variations in filling and handling for commercial scale production.

Tablet weight and appearance may be affected by equipment and tooling conditions; therefore, in-process monitoring is essential for reproducibility during commercial production.

Analytical Testing and Finished-Product Quality

The quality testing of Cefixime 200MG Ofloxacin 200MG Tablets includes identification and assay of the active ingredients and the physical specifications of the tablet. Identification and assay help to find out the composition of the active ingredients. The uniformity of dosage –unit is significant in combining tablets and is tested by the sampling and assay.

Finished-product testing includes appearance, average weight, weight variation, hardness, friability, disintegration, dissolution, moisture and related substances, and various other quality factors Dissolution tests are used to establish the released properties of both active components, absorbed in the tablet shell, during routine use, in line with approved requirements for the product as stated in the pharmaceutical standards.

The analytical techniques should be specific, precise and accurate for the determination of Cefixime and Ofloxacin, as well as when both the analytes are estimated together in the same matrix, that is within the tablet matrix itself. Batch documentation should include raw material data, dispensing amount, blend specifications, compression specifications, in-process inspection records, lab reports, and packaging information. Complete batch records are indicative of traceability as well as process trends over time.

Stability, Packaging, and PCD Pharma Integration

Fabrication of Packaging Cefixime 200MG Ofloxacin 200MG Tablet The physical and chemical properties of the active pharmaceutical ingredients (API) and the finished product will be taken into account when designing the packaging. The packing material's specifications, such as blister packs, strips, and compatible containers, should be compatible with the package's approved configuration. The packaging's capacity to safeguard the pack from the environment and moisture must be determined.

Stability studies observe the assay of both ingredients, disintegration, dissolution, appearance, friability, moisture content, hardness, and other parameters over the shelf life. The container-closure system must be evaluated under storage conditions to demonstrate that the package remains acceptable throughout the shelf life.

For the PCD Pharma Franchise of Cefixime 200MG Ofloxacin 200MG Tablets, the combination tablet is supported by common specifications, specified processes, controlled packaging, and documented quality systems. The development of this fixed dose combination tablet combines skillful management of active ingredients, powder attributes, blend uniformity, compression technology, dose-unit uniformity, dissolution performance, analytical testing, packaging compatibility, and stability. Controlled of all of these stages maintains the solid oral dosage form with specified pharmaceutical quality attributes.